The Use of Novel PI3K Inhibitors in CLL - Dr Jennifer Brown MD Dana-Farber Cancer Institute

[lankisterguy]

The Use of Novel PI3K Inhibitors in CLL

onclive.com/peer-exchange/r...

youtu.be/FXsfkd4Spgk(Not working as expected?)

Panelists: William G. Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center; Steven Coutre, MD, Stanford University Medical Center; Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute; Nicole Lamanna, MD, Columbia University Medical Center; Shuo Ma, MD, PhD, Robert H. Lurie Comprehensive Cancer Center

Published: Tuesday, Feb 13, 2018

There are several different videos from this panel discussion- you can go to the website and select others for viewing. You may need to register to view.

onclive.com/peer-exchange/r...

Len

[Justasheet1]

Len,

Not the go to drug but it might get somebody to transplant or Car-T

Some like CllCanada Chris did pretty good I believe.

Jeff

[Cllcanada Top Poster CURE Hero in reply to Justasheet1]

Absolutely Jeff... I did very well on Zydelig (idelalisib)/rituxan , minor bowel issues from it... doctors won't use it because they lack experience and it has black boxes and substantual prophylactics...

My CLL doc was an associate of Dr. Brown.. so has this clinical trial experience, as well..,

~chris

[MsLockYourPosts Passed Volunteer in reply to Cllcanada]

Cllcanada Where does ofatuzumab fit into the picture these days? I have a friend who has been getting it forever. Her doctor isn't a specialist. MDA recommended Ibrutinib, but for some reason she is dead set against it. Maybe the fear of potential costs?

[Cllcanada Top Poster CURE Hero in reply to MsLockYourPosts]

Ofatumumab has been sold and now belongs to Novartis.. they got it approved for maintenance therapy in the EU, but last fall announced they were withdrawing the use of it in Europe... so, its in decline, actually it never could compete with rituxan.

Your friend should consider gazyva with or without chlorambucil and get off the continuous drip, drip...

But Imbruvica (ibrutinib) certainly would be the way to go... I think

~chris

[lankisterguy Administrator Volunteer in reply to Justasheet1]

When you have fast progressing disease like mine, having many drugs to choose from is important.

I became resistant to Idelalisib and get skin rash from Ibrutinib. If I have a problem with Venetoclax, I will need to try Alcalabrutinib and/or broader version of Idelalisib like this new drug.

My wife and I think of it as getting another stretch of runway every few years. We need to have more approved soon.

Len

[Justasheet1 in reply to lankisterguy]

Len,

I agree. All the clinical trials I see now are pretty much Car-T or NK transplant.

I’m not ready for that yet unless they get a handle on the toxicities.

Jeff

[Cllcanada Top Poster CURE Hero in reply to lankisterguy]

Duvelisib is in the batter's box.. should be FDAed next month.

~chris